If Procept's Management is aware of and reads these web pages - please publish the results of Dr. Lut Van Damne's presentation (October 22, 1997) at the International Congress of Sexually Transmitted Diseases in Seville, Spain.
Also, release a press release on the status of your TB effort. The atttached is an excellent example of how one company communicates effectively with the public (the result is an upward moving stock price):
CEL-SCI Corporation Responds to Inquiries About the Status of Its
Tuberculosis Program
ALEXANDRIA, Va., Oct. 23 /PRNewswire/ -- Numerous new items around the country today report that multiple drug
resistant Tuberculosis (TB), which is difficult or impossible to treat, is on the rise. In fact, 1 in 10 TB cases worldwide resists
common treatment. TB kills about 3 million people a year. Apparently in response to these reports, CEL-SCI
CORPORATION (Amex:HIV) has received many inquiries in regard to the status of its TB program.
CEL-SCI's L.E.A.P.S. vaccine/treatment against TB has produced promising results, showing potential efficacy against
multiple strains of TB, including multiple drug resistant strains. Published findings with CEL-SCI's L.E.A.P.S. TB
vaccine/treatment showed that the antibodies induced by CEL-SCI's vaccine/treatment recognize various TB strains much
better than antibodies produced by conventional technology. Those strains included two multiple drug resistant strains and
five drug resistant strains of the type that infect healthy individuals and six species of mycobacteria that infect primarily
immunocompromised patients (e.g. AIDS). CEL-SCI's findings may lead to the design of a TB vaccine/treatment which
would be effective against multiple strains of TB, including multiple drug resistant strains. Research is continuing to optimize
the immune responses to CEL-SCI's TB vaccine/treatment. The L.E.A.P.S. vaccine/treatment technology was recently
shown to prevent herpes simplex infection in mice.
CEL-SCI Corporation is a pioneer in the field of natural immunotherapy. The Company is developing immune based
treatments for cancer, AIDS, tuberculosis, malaria and herpes simplex.
''CEL-SCI press releases are available through Company News On-Call by fax, 800-758-5804, Ext. 445563, or at
prnewswire.com on the Internet.''
When used in this report, the words ''intend,'' ''believes,'' ''anticipated'' and ''expects'' and similar expressions are intended
to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results
to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to
duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown
to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential
products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its
report on Form 10-K for the year ended September 30, 1996. The Company undertakes no obligation to publicly release
the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. |
